+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Office Based Labs Market - Global Forecast 2026-2032- Product Image
Office Based Labs Market - Global Forecast 2026-2032- Product Image
Sale

Office Based Labs Market - Global Forecast 2026-2032

  • Report

  • 198 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 5470716
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Office Based Labs Market is projected to reach USD 36.24 Billion in 2026. It is expected to continue growing at a CAGR of 7.35%, reaching USD 55.63 Billion by 2032.

Office based labs, also called OBLs, are reshaping outpatient vascular, interventional radiology, cardiology, pain management, and image guided care by moving appropriate procedures from hospital operating rooms into specialized physician office settings. The model is gaining relevance as health systems, independent physicians, payers, and device manufacturers look for lower acuity sites that can deliver timely access, procedural efficiency, and a more patient centered experience.

The market is supported by durable healthcare trends: growth in minimally invasive procedures, aging populations with peripheral artery disease and venous disease, payer interest in lower cost sites of care, and continued advances in imaging, catheters, guidewires, atherectomy, embolization, and anesthesia monitoring. For executive decision making, the office based labs landscape should be viewed as a convergence of outpatient surgery, interventional medicine, healthcare real estate, reimbursement strategy, and medical technology commercialization.

Transformative Shifts in the Office Based Labs Landscape

The most important shift in the office based labs landscape is the migration of clinically appropriate procedures to ambulatory and physician office environments. Medicare policy, commercial payer utilization management, and patient demand for convenience continue to encourage site of care optimization, while accreditation, quality reporting, and stronger infection control protocols are raising expectations for OBL operators.

A second transformative shift is consolidation. Independent practices are increasingly partnering with management services organizations, ambulatory surgery center platforms, private equity backed groups, and hospital joint ventures to manage compliance, capital equipment, staffing, billing, and referral development. This is creating a more sophisticated market in which scale, documentation quality, and clinical governance are becoming as important as procedure volume.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative force across the office based labs value chain. In imaging, AI enabled reconstruction, segmentation, and workflow support can help clinicians interpret vascular anatomy, improve case planning, and reduce variability when used under appropriate clinical oversight. In operations, predictive analytics can improve scheduling, inventory management, claims review, patient outreach, and revenue cycle performance.

The impact is not limited to automation. AI can support risk stratification, identify patients who may benefit from earlier intervention, and help practices benchmark outcomes against internal quality indicators. However, adoption must be governed by HIPAA compliance, cybersecurity controls, bias monitoring, FDA cleared use cases when applicable, and physician accountability for final clinical decisions.

Key Regional Insights

North America remains the most mature region for office based labs due to advanced outpatient reimbursement structures, strong physician ownership models, established medical device distribution, and high demand for minimally invasive vascular and interventional procedures. The United States leads regional activity, while Canada shows selective adoption shaped by provincial healthcare funding, hospital capacity pressures, and cautious integration of physician office procedures into publicly financed care pathways.

Europe is advancing through ambulatory care reforms, although adoption varies by national payment systems, physician employment models, and facility licensing requirements. Germany, France, Italy, Spain, and the United Kingdom show demand for day case efficiency, while the European Union increasingly emphasizes patient safety, device traceability, data protection, and cross border quality standards under evolving medical device regulation. Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia invest in outpatient capacity, private specialty care, and image guided technologies to address chronic disease burdens and hospital congestion. Latin America, led by Brazil and Mexico, is developing through private healthcare networks, urban specialty clinics, and growing access to minimally invasive care. The Middle East, particularly GCC countries, is investing in premium outpatient infrastructure, digital health, and specialist-led care models, while Africa remains earlier stage, with activity concentrated in major metropolitan private healthcare centers and constrained by uneven specialist availability, imaging access, and reimbursement depth.

Key Group Insights

The G7 markets anchor much of the office based labs opportunity because they combine aging populations, advanced device adoption, established specialist networks, and mature reimbursement or private payment channels. NATO countries overlap with many high income healthcare systems where supply chain resilience, device cybersecurity, critical infrastructure protection, and healthcare modernization are strategic priorities. The European Union adds a highly regulated environment that rewards quality systems, data protection, clinical evidence, device traceability, and compliance with medical device rules.

BRICS markets are important for long term growth because of rising noncommunicable disease burdens, expanding middle class access, urban private healthcare development, and government investment in specialty care, although reimbursement fragmentation, procurement complexity, and infrastructure gaps can slow adoption. ASEAN markets are developing around urban private hospitals, specialty clinics, and cross border care hubs, with medical tourism supporting demand in select countries. GCC markets are differentiated by government backed healthcare transformation, international provider partnerships, high healthcare infrastructure investment, and demand for high acuity outpatient services delivered in modern facilities.

Key Country Insights

The United States is the primary benchmark for office based labs, driven by physician entrepreneurship, payer site of care policies, established coding pathways, and widespread use of outpatient endovascular and interventional procedures. Canada is more selective because public funding structures, provincial planning, and hospital-based specialist access shape adoption, while Mexico and Brazil are advancing through private sector specialty networks, urban demand, and expanding use of minimally invasive vascular and interventional care. In Europe, the United Kingdom, Germany, France, Italy, and Spain are moving toward more outpatient treatment and day case efficiency, but reimbursement rules, physician employment models, facility licensing, and procurement processes differ significantly by country.

China and India present large demand pools due to population scale, diabetes, vascular disease, cardiovascular risk factors, and expanding private healthcare investment. Japan, South Korea, and Australia are attractive for advanced imaging, high quality standards, trained specialist workforces, and strong adoption of precision procedural technologies. Russia shows demand for interventional care but faces constraints linked to procurement, sanctions exposure, technology access, and healthcare funding volatility. Across all countries, success depends on aligning procedure selection, reimbursement, quality documentation, emergency preparedness, radiation safety, and referral relationships with local regulatory expectations.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically appropriate case selection, accreditation readiness, and defensible documentation before expanding procedure volume. OBL operators need standardized protocols for patient screening, emergency transfer agreements, radiation safety, infection prevention, sedation monitoring, device tracking, staff credentialing, adverse event review, and outcomes measurement to protect patients and support payer confidence.

Medical device companies should build OBL specific commercialization strategies that include physician training, staff education, consignment models, service uptime, coding support, compliance guidance, and evidence generation for outpatient use. Investors and strategic partners should evaluate reimbursement exposure, physician alignment, referral concentration, compliance controls, capital equipment needs, and local competitive intensity. The most resilient strategies will combine operational discipline with high quality clinical outcomes, transparent patient communication, and continuous monitoring of payer and regulatory changes.

Research Methodology

This executive summary is based on a triangulated research approach combining public regulatory information, reimbursement policy review, medical device and healthcare services industry analysis, clinical practice trends, and secondary research from credible sources such as government health agencies, payer policy documents, accreditation bodies, professional society guidance, and peer reviewed literature. The methodology emphasizes verifiable market drivers and operational realities rather than speculative forecasts.

Insights were validated by comparing regional healthcare infrastructure, outpatient care policies, demographic demand indicators, chronic disease patterns, and procedure migration trends across major economies. The analysis also considers qualitative factors including physician practice models, capital equipment requirements, facility accreditation, data privacy obligations, emergency transfer protocols, radiation safety standards, and the evolving role of artificial intelligence in image guided outpatient care.

Conclusion

Office based labs are becoming a strategic pillar of outpatient specialty care by combining minimally invasive medicine, patient convenience, and site of care efficiency. Their expansion is strongest where reimbursement supports office based procedures, physicians have access to capital and trained staff, and quality safeguards are well established.

The next phase of the market will be defined by disciplined growth, AI enabled workflow improvement, stronger compliance expectations, more rigorous outcomes documentation, and deeper collaboration among physicians, payers, device manufacturers, and health systems. Organizations that balance access, affordability, patient safety, and measurable outcomes will be best positioned to lead in the office based labs market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Office Based Labs Market, by Product Type
7.1. Introduction
7.2. Automated Analyzers
7.2.1. Discrete
7.2.2. Integrated
7.3. Next-Generation Sequencing
7.3.1. Targeted Panel Sequencing
7.3.2. Whole Genome Sequencing
7.4. Point-of-Care Devices
7.4.1. Benchtop
7.4.2. Handheld
8. Office Based Labs Market, by Technology Type
8.1. Introduction
8.2. Clinical Chemistry
8.2.1. Continuous Flow
8.2.2. Discrete Analyzers
8.3. Coagulation & Hemostasis
8.3.1. Platelet Function Testing
8.3.2. Prothrombin Time INR
8.4. Hematology
8.4.1. Automated Hematology Analyzers
8.4.2. Manual Cell Counters
8.5. Immunoassay
8.5.1. Chemiluminescence
8.5.2. Enzyme-Linked Immunoassay
8.6. Molecular Diagnostics
8.6.1. Fluorescence In Situ Hybridization
8.6.2. Next-Generation Sequencing
8.6.3. Polymerase Chain Reaction
9. Office Based Labs Market, by Test Type
9.1. Introduction
9.2. Point-of-Care Tests
9.2.1. Glucose Monitoring
9.2.2. Lipid Testing
9.3. Routine Tests
9.3.1. Basic Panels
9.3.2. Comprehensive Panels
9.4. Specialized Tests
9.4.1. Biomarker Tests
9.4.2. Genetic Tests
10. Office Based Labs Market, by Application
10.1. Introduction
10.2. Disease Monitoring
10.2.1. Acute Condition Monitoring
10.2.2. Chronic Disease Monitoring
10.3. Healthcare Diagnostics
10.3.1. Infectious Diseases
10.3.2. Oncology Diagnostics
10.4. Preventive Screening
10.4.1. Cardiovascular Screening
10.4.2. Metabolic Screening
11. Office Based Labs Market, by End User
11.1. Introduction
11.2. Hospital Outreach Laboratories
11.3. Independent Reference Laboratories
11.4. Physician Office Laboratories
12. Office Based Labs Market, by Region
12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East
13. Office Based Labs Market, by Group
13.1. NATO
13.2. G7
13.3. BRICS
13.4. European Union
13.5. ASEAN
13.6. GCC
14. Office Based Labs Market, by Country
14.1. China
14.2. United States
14.3. Japan
14.4. India
14.5. Germany
14.6. United Kingdom
14.7. Australia
14.8. France
14.9. South Korea
14.10. Italy
14.11. Canada
14.12. Russia
14.13. Brazil
14.14. Mexico
14.15. Spain
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Abbott Laboratories
16.2. Abionic SA
16.3. ARKRAY, Inc.
16.4. Beckman Coulter, Inc.
16.5. Becton, Dickinson and Company
16.6. bioMérieux SA
16.7. Boule Diagnostics
16.8. Danaher Corporation
16.9. EKF Diagnostics Holdings plc
16.10. F. Hoffmann-La Roche Ltd
16.11. Ortho Clinical Diagnostics Inc.
16.12. QIAGEN N.V.
16.13. Siemens Healthineers AG
16.14. STRATEC SE
16.15. Sysmex Corporation
16.16. Thermo Fisher Scientific Inc.
List of Figures
FIGURE 1. GLOBAL OFFICE BASED LABS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL OFFICE BASED LABS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL OFFICE BASED LABS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL OFFICE BASED LABS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL OFFICE BASED LABS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL OFFICE BASED LABS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL OFFICE BASED LABS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL OFFICE BASED LABS MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL OFFICE BASED LABS MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL OFFICE BASED LABS MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL OFFICE BASED LABS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL OFFICE BASED LABS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL OFFICE BASED LABS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL OFFICE BASED LABS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL OFFICE BASED LABS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL OFFICE BASED LABS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL OFFICE BASED LABS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL OFFICE BASED LABS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL OFFICE BASED LABS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL OFFICE BASED LABS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL OFFICE BASED LABS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL OFFICE BASED LABS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL OFFICE BASED LABS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL OFFICE BASED LABS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL OFFICE BASED LABS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL OFFICE BASED LABS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL AUTOMATED ANALYZERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL AUTOMATED ANALYZERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL AUTOMATED ANALYZERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL DISCRETE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL DISCRETE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL DISCRETE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL INTEGRATED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL INTEGRATED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL INTEGRATED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL TARGETED PANEL SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL TARGETED PANEL SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL TARGETED PANEL SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL POINT-OF-CARE DEVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL POINT-OF-CARE DEVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL POINT-OF-CARE DEVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL BENCHTOP MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL BENCHTOP MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL BENCHTOP MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL HANDHELD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL HANDHELD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL HANDHELD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL OFFICE BASED LABS MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL CLINICAL CHEMISTRY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL CLINICAL CHEMISTRY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CLINICAL CHEMISTRY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL CONTINUOUS FLOW MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL CONTINUOUS FLOW MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL CONTINUOUS FLOW MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL DISCRETE ANALYZERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL DISCRETE ANALYZERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL DISCRETE ANALYZERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL COAGULATION & HEMOSTASIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL COAGULATION & HEMOSTASIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL COAGULATION & HEMOSTASIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL PLATELET FUNCTION TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL PLATELET FUNCTION TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL PLATELET FUNCTION TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL PROTHROMBIN TIME INR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL PROTHROMBIN TIME INR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL PROTHROMBIN TIME INR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL HEMATOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL HEMATOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL HEMATOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL AUTOMATED HEMATOLOGY ANALYZERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL AUTOMATED HEMATOLOGY ANALYZERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL AUTOMATED HEMATOLOGY ANALYZERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL MANUAL CELL COUNTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL MANUAL CELL COUNTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL MANUAL CELL COUNTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL IMMUNOASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL CHEMILUMINESCENCE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL CHEMILUMINESCENCE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL CHEMILUMINESCENCE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ENZYME-LINKED IMMUNOASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ENZYME-LINKED IMMUNOASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL ENZYME-LINKED IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL FLUORESCENCE IN SITU HYBRIDIZATION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL NEXT-GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL OFFICE BASED LABS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL POINT-OF-CARE TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL POINT-OF-CARE TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL POINT-OF-CARE TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL GLUCOSE MONITORING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL GLUCOSE MONITORING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL GLUCOSE MONITORING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL LIPID TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL LIPID TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL LIPID TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL ROUTINE TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL ROUTINE TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL ROUTINE TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL BASIC PANELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL BASIC PANELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL BASIC PANELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL COMPREHENSIVE PANELS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL COMPREHENSIVE PANELS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL COMPREHENSIVE PANELS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL SPECIALIZED TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL SPECIALIZED TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL SPECIALIZED TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL BIOMARKER TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL BIOMARKER TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL BIOMARKER TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL GENETIC TESTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL GENETIC TESTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL GENETIC TESTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 108. GLOBAL OFFICE BASED LABS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 109. GLOBAL DISEASE MONITORING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 110. GLOBAL DISEASE MONITORING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 111. GLOBAL DISEASE MONITORING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 112. GLOBAL ACUTE CONDITION MONITORING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. GLOBAL ACUTE CONDITION MONITORING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 114. GLOBAL ACUTE CONDITION MONITORING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 115. GLOBAL CHRONIC DISEASE MONITORING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. GLOBAL CHRONIC DISEASE MONITORING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 117. GLOBAL CHRONIC DISEASE MONITORING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 118. GLOBAL HEALTHCARE DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 119. GLOBAL HEALTHCARE DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 120. GLOBAL HEALTHCARE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 121. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 124. GLOBAL ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. GLOBAL ONCOLOGY DIAGNOSTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 126. GLOBAL ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 127. GLOBAL PREVENTIVE SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 128. GLOBAL PREVENTIVE SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 129. GLOBAL PREVENTIVE SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 130. GLOBAL CARDIOVASCULAR SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. GLOBAL CARDIOVASCULAR SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 132. GLOBAL CARDIOVASCULAR SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 133. GLOBAL METABOLIC SCREENING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 134. GLOBAL METABOLIC SCREENING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 135. GLOBAL METABOLIC SCREENING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 136. GLOBAL OFFICE BASED LABS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 137. GLOBAL HOSPITAL OUTREACH LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 138. GLOBAL HOSPITAL OUTREACH LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 139. GLOBAL HOSPITAL OUTREACH LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 140. GLOBAL INDEPENDENT REFERENCE LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 141. GLOBAL INDEPENDENT REFERENCE LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 142. GLOBAL INDEPENDENT REFERENCE LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 143. GLOBAL PHYSICIAN OFFICE LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 144. GLOBAL PHYSICIAN OFFICE LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 145. GLOBAL PHYSICIAN OFFICE LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 146. GLOBAL OFFICE BASED LABS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 147. ASIA-PACIFIC OFFICE BASED LABS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC OFFICE BASED LABS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC OFFICE BASED LABS MARKET SIZE, BY AUTOMATED ANALYZERS, 2017-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC OFFICE BASED LABS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC OFFICE BASED LABS MARKET SIZE, BY POINT-OF-CARE DEVICES, 2017-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC OFFICE BASED LABS MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC OFFICE BASED LABS MARKET SIZE, BY CLINICAL CHEMISTRY, 2017-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC OFFICE BASED LABS MARKET SIZE, BY COAGULATION & HEMOSTASIS, 2017-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC OFFICE BASED LABS MARKET SIZE, BY HEMATOLOGY, 2017-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC OFFICE BASED LABS MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC OFFICE BASED LABS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC OFFICE BASED LABS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC OFFICE BASED LABS MARKET SIZE, BY POINT-OF-CARE TESTS, 2017-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC OFFICE BASED LABS MARKET SIZE, BY ROUTINE TESTS, 2017-2032 (USD MILLION)
TABLE 161. ASIA-PACIFIC OFFICE BASED LABS MARKET SIZE, BY SPECIALIZED TESTS, 2017-2032 (USD MILLION)
TABLE 162. ASIA-PACIFIC OFFICE BASED LABS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 163. ASIA-PACIFIC OFFICE BASED LABS MARKET SIZE, BY DISEASE MONITORING, 2017-2032 (USD MILLION)
TABLE 164. ASIA-PACIFIC OFFICE BASED LABS MARKET SIZE, BY HEALTHCARE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 165. ASIA-PACIFIC OFFICE BASED LABS MARKET SIZE, BY PREVENTIVE SCREENING, 2017-2032 (USD MILLION)
TABLE 166. ASIA-PACIFIC OFFICE BASED LABS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 167. EUROPE OFFICE BASED LABS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 168. EUROPE OFFICE BASED LABS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 169. EUROPE OFFICE BASED LABS MARKET SIZE, BY AUTOMATED ANALYZERS, 2017-2032 (USD MILLION)
TABLE 170. EUROPE OFFICE BASED LABS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 171. EUROPE OFFICE BASED LABS MARKET SIZE, BY POINT-OF-CARE DEVICES, 2017-2032 (USD MILLION)
TABLE 172. EUROPE OFFICE BASED LABS MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 173. EUROPE OFFICE BASED LABS MARKET SIZE, BY CLINICAL CHEMISTRY, 2017-2032 (USD MILLION)
TABLE 174. EUROPE OFFICE BASED LABS MARKET SIZE, BY COAGULATION & HEMOSTASIS, 2017-2032 (USD MILLION)
TABLE 175. EUROPE OFFICE BASED LABS MARKET SIZE, BY HEMATOLOGY, 2017-2032 (USD MILLION)
TABLE 176. EUROPE OFFICE BASED LABS MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 177. EUROPE OFFICE BASED LABS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 178. EUROPE OFFICE BASED LABS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 179. EUROPE OFFICE BASED LABS MARKET SIZE, BY POINT-OF-CARE TESTS, 2017-2032 (USD MILLION)
TABLE 180. EUROPE OFFICE BASED LABS MARKET SIZE, BY ROUTINE TESTS, 2017-2032 (USD MILLION)
TABLE 181. EUROPE OFFICE BASED LABS MARKET SIZE, BY SPECIALIZED TESTS, 2017-2032 (USD MILLION)
TABLE 182. EUROPE OFFICE BASED LABS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 183. EUROPE OFFICE BASED LABS MARKET SIZE, BY DISEASE MONITORING, 2017-2032 (USD MILLION)
TABLE 184. EUROPE OFFICE BASED LABS MARKET SIZE, BY HEALTHCARE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 185. EUROPE OFFICE BASED LABS MARKET SIZE, BY PREVENTIVE SCREENING, 2017-2032 (USD MILLION)
TABLE 186. EUROPE OFFICE BASED LABS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 187. NORTH AMERICA OFFICE BASED LABS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 188. NORTH AMERICA OFFICE BASED LABS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 189. NORTH AMERICA OFFICE BASED LABS MARKET SIZE, BY AUTOMATED ANALYZERS, 2017-2032 (USD MILLION)
TABLE 190. NORTH AMERICA OFFICE BASED LABS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 191. NORTH AMERICA OFFICE BASED LABS MARKET SIZE, BY POINT-OF-CARE DEVICES, 2017-2032 (USD MILLION)
TABLE 192. NORTH AMERICA OFFICE BASED LABS MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 193. NORTH AMERICA OFFICE BASED LABS MARKET SIZE, BY CLINICAL CHEMISTRY, 2017-2032 (USD MILLION)
TABLE 194. NORTH AMERICA OFFICE BASED LABS MARKET SIZE, BY COAGULATION & HEMOSTASIS, 2017-2032 (USD MILLION)
TABLE 195. NORTH AMERICA OFFICE BASED LABS MARKET SIZE, BY HEMATOLOGY, 2017-2032 (USD MILLION)
TABLE 196. NORTH AMERICA OFFICE BASED LABS MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 197. NORTH AMERICA OFFICE BASED LABS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 198. NORTH AMERICA OFFICE BASED LABS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 199. NORTH AMERICA OFFICE BASED LABS MARKET SIZE, BY POINT-OF-CARE TESTS, 2017-2032 (USD MILLION)
TABLE 200. NORTH AMERICA OFFICE BASED LABS MARKET SIZE, BY ROUTINE TESTS, 2017-2032 (USD MILLION)
TABLE 201. NORTH AMERICA OFFICE BASED LABS MARKET SIZE, BY SPECIALIZED TESTS, 2017-2032 (USD MILLION)
TABLE 202. NORTH AMERICA OFFICE BASED LABS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 203. NORTH AMERICA OFFICE BASED LABS MARKET SIZE, BY DISEASE MONITORING, 2017-2032 (USD MILLION)
TABLE 204. NORTH AMERICA OFFICE BASED LABS MARKET SIZE, BY HEALTHCARE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 205. NORTH AMERICA OFFICE BASED LABS MARKET SIZE, BY PREVENTIVE SCREENING, 2017-2032 (USD MILLION)
TABLE 206. NORTH AMERICA OFFICE BASED LABS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 207. LATIN AMERICA OFFICE BASED LABS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 208. LATIN AMERICA OFFICE BASED LABS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 209. LATIN AMERICA OFFICE BASED LABS MARKET SIZE, BY AUTOMATED ANALYZERS, 2017-2032 (USD MILLION)
TABLE 210. LATIN AMERICA OFFICE BASED LABS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 211. LATIN AMERICA OFFICE BASED LABS MARKET SIZE, BY POINT-OF-CARE DEVICES, 2017-2032 (USD MILLION)
TABLE 212. LATIN AMERICA OFFICE BASED LABS MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 213. LATIN AMERICA OFFICE BASED LABS MARKET SIZE, BY CLINICAL CHEMISTRY, 2017-2032 (USD MILLION)
TABLE 214. LATIN AMERICA OFFICE BASED LABS MARKET SIZE, BY COAGULATION & HEMOSTASIS, 2017-2032 (USD MILLION)
TABLE 215. LATIN AMERICA OFFICE BASED LABS MARKET SIZE, BY HEMATOLOGY, 2017-2032 (USD MILLION)
TABLE 216. LATIN AMERICA OFFICE BASED LABS MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 217. LATIN AMERICA OFFICE BASED LABS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 218. LATIN AMERICA OFFICE BASED LABS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 219. LATIN AMERICA OFFICE BASED LABS MARKET SIZE, BY POINT-OF-CARE TESTS, 2017-2032 (USD MILLION)
TABLE 220. LATIN AMERICA OFFICE BASED LABS MARKET SIZE, BY ROUTINE TESTS, 2017-2032 (USD MILLION)
TABLE 221. LATIN AMERICA OFFICE BASED LABS MARKET SIZE, BY SPECIALIZED TESTS, 2017-2032 (USD MILLION)
TABLE 222. LATIN AMERICA OFFICE BASED LABS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 223. LATIN AMERICA OFFICE BASED LABS MARKET SIZE, BY DISEASE MONITORING, 2017-2032 (USD MILLION)
TABLE 224. LATIN AMERICA OFFICE BASED LABS MARKET SIZE, BY HEALTHCARE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 225. LATIN AMERICA OFFICE BASED LABS MARKET SIZE, BY PREVENTIVE SCREENING, 2017-2032 (USD MILLION)
TABLE 226. LATIN AMERICA OFFICE BASED LABS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 227. AFRICA OFFICE BASED LABS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 228. AFRICA OFFICE BASED LABS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 229. AFRICA OFFICE BASED LABS MARKET SIZE, BY AUTOMATED ANALYZERS, 2017-2032 (USD MILLION)
TABLE 230. AFRICA OFFICE BASED LABS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 231. AFRICA OFFICE BASED LABS MARKET SIZE, BY POINT-OF-CARE DEVICES, 2017-2032 (USD MILLION)
TABLE 232. AFRICA OFFICE BASED LABS MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 233. AFRICA OFFICE BASED LABS MARKET SIZE, BY CLINICAL CHEMISTRY, 2017-2032 (USD MILLION)
TABLE 234. AFRICA OFFICE BASED LABS MARKET SIZE, BY COAGULATION & HEMOSTASIS, 2017-2032 (USD MILLION)
TABLE 235. AFRICA OFFICE BASED LABS MARKET SIZE, BY HEMATOLOGY, 2017-2032 (USD MILLION)
TABLE 236. AFRICA OFFICE BASED LABS MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 237. AFRICA OFFICE BASED LABS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 238. AFRICA OFFICE BASED LABS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 239. AFRICA OFFICE BASED LABS MARKET SIZE, BY POINT-OF-CARE TESTS, 2017-2032 (USD MILLION)
TABLE 240. AFRICA OFFICE BASED LABS MARKET SIZE, BY ROUTINE TESTS, 2017-2032 (USD MILLION)
TABLE 241. AFRICA OFFICE BASED LABS MARKET SIZE, BY SPECIALIZED TESTS, 2017-2032 (USD MILLION)
TABLE 242. AFRICA OFFICE BASED LABS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 243. AFRICA OFFICE BASED LABS MARKET SIZE, BY DISEASE MONITORING, 2017-2032 (USD MILLION)
TABLE 244. AFRICA OFFICE BASED LABS MARKET SIZE, BY HEALTHCARE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 245. AFRICA OFFICE BASED LABS MARKET SIZE, BY PREVENTIVE SCREENING, 2017-2032 (USD MILLION)
TABLE 246. AFRICA OFFICE BASED LABS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 247. MIDDLE EAST OFFICE BASED LABS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 248. MIDDLE EAST OFFICE BASED LABS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 249. MIDDLE EAST OFFICE BASED LABS MARKET SIZE, BY AUTOMATED ANALYZERS, 2017-2032 (USD MILLION)
TABLE 250. MIDDLE EAST OFFICE BASED LABS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 251. MIDDLE EAST OFFICE BASED LABS MARKET SIZE, BY POINT-OF-CARE DEVICES, 2017-2032 (USD MILLION)
TABLE 252. MIDDLE EAST OFFICE BASED LABS MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 253. MIDDLE EAST OFFICE BASED LABS MARKET SIZE, BY CLINICAL CHEMISTRY, 2017-2032 (USD MILLION)
TABLE 254. MIDDLE EAST OFFICE BASED LABS MARKET SIZE, BY COAGULATION & HEMOSTASIS, 2017-2032 (USD MILLION)
TABLE 255. MIDDLE EAST OFFICE BASED LABS MARKET SIZE, BY HEMATOLOGY, 2017-2032 (USD MILLION)
TABLE 256. MIDDLE EAST OFFICE BASED LABS MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 257. MIDDLE EAST OFFICE BASED LABS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 258. MIDDLE EAST OFFICE BASED LABS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 259. MIDDLE EAST OFFICE BASED LABS MARKET SIZE, BY POINT-OF-CARE TESTS, 2017-2032 (USD MILLION)
TABLE 260. MIDDLE EAST OFFICE BASED LABS MARKET SIZE, BY ROUTINE TESTS, 2017-2032 (USD MILLION)
TABLE 261. MIDDLE EAST OFFICE BASED LABS MARKET SIZE, BY SPECIALIZED TESTS, 2017-2032 (USD MILLION)
TABLE 262. MIDDLE EAST OFFICE BASED LABS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 263. MIDDLE EAST OFFICE BASED LABS MARKET SIZE, BY DISEASE MONITORING, 2017-2032 (USD MILLION)
TABLE 264. MIDDLE EAST OFFICE BASED LABS MARKET SIZE, BY HEALTHCARE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 265. MIDDLE EAST OFFICE BASED LABS MARKET SIZE, BY PREVENTIVE SCREENING, 2017-2032 (USD MILLION)
TABLE 266. MIDDLE EAST OFFICE BASED LABS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 267. GLOBAL OFFICE BASED LABS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 268. NATO OFFICE BASED LABS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 269. NATO OFFICE BASED LABS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 270. NATO OFFICE BASED LABS MARKET SIZE, BY AUTOMATED ANALYZERS, 2017-2032 (USD MILLION)
TABLE 271. NATO OFFICE BASED LABS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 272. NATO OFFICE BASED LABS MARKET SIZE, BY POINT-OF-CARE DEVICES, 2017-2032 (USD MILLION)
TABLE 273. NATO OFFICE BASED LABS MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 274. NATO OFFICE BASED LABS MARKET SIZE, BY CLINICAL CHEMISTRY, 2017-2032 (USD MILLION)
TABLE 275. NATO OFFICE BASED LABS MARKET SIZE, BY COAGULATION & HEMOSTASIS, 2017-2032 (USD MILLION)
TABLE 276. NATO OFFICE BASED LABS MARKET SIZE, BY HEMATOLOGY, 2017-2032 (USD MILLION)
TABLE 277. NATO OFFICE BASED LABS MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 278. NATO OFFICE BASED LABS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 279. NATO OFFICE BASED LABS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 280. NATO OFFICE BASED LABS MARKET SIZE, BY POINT-OF-CARE TESTS, 2017-2032 (USD MILLION)
TABLE 281. NATO OFFICE BASED LABS MARKET SIZE, BY ROUTINE TESTS, 2017-2032 (USD MILLION)
TABLE 282. NATO OFFICE BASED LABS MARKET SIZE, BY SPECIALIZED TESTS, 2017-2032 (USD MILLION)
TABLE 283. NATO OFFICE BASED LABS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 284. NATO OFFICE BASED LABS MARKET SIZE, BY DISEASE MONITORING, 2017-2032 (USD MILLION)
TABLE 285. NATO OFFICE BASED LABS MARKET SIZE, BY HEALTHCARE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 286. NATO OFFICE BASED LABS MARKET SIZE, BY PREVENTIVE SCREENING, 2017-2032 (USD MILLION)
TABLE 287. NATO OFFICE BASED LABS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 288. G7 OFFICE BASED LABS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 289. G7 OFFICE BASED LABS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 290. G7 OFFICE BASED LABS MARKET SIZE, BY AUTOMATED ANALYZERS, 2017-2032 (USD MILLION)
TABLE 291. G7 OFFICE BASED LABS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 292. G7 OFFICE BASED LABS MARKET SIZE, BY POINT-OF-CARE DEVICES, 2017-2032 (USD MILLION)
TABLE 293. G7 OFFICE BASED LABS MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 294. G7 OFFICE BASED LABS MARKET SIZE, BY CLINICAL CHEMISTRY, 2017-2032 (USD MILLION)
TABLE 295. G7 OFFICE BASED LABS MARKET SIZE, BY COAGULATION & HEMOSTASIS, 2017-2032 (USD MILLION)
TABLE 296. G7 OFFICE BASED LABS MARKET SIZE, BY HEMATOLOGY, 2017-2032 (USD MILLION)
TABLE 297. G7 OFFICE BASED LABS MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 298. G7 OFFICE BASED LABS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 299. G7 OFFICE BASED LABS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 300. G7 OFFICE BASED LABS MARKET SIZE, BY POINT-OF-CARE TESTS, 2017-2032 (USD MILLION)
TABLE 301. G7 OFFICE BASED LABS MARKET SIZE, BY ROUTINE TESTS, 2017-2032 (USD MILLION)
TABLE 302. G7 OFFICE BASED LABS MARKET SIZE, BY SPECIALIZED TESTS, 2017-2032 (USD MILLION)
TABLE 303. G7 OFFICE BASED LABS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 304. G7 OFFICE BASED LABS MARKET SIZE, BY DISEASE MONITORING, 2017-2032 (USD MILLION)
TABLE 305. G7 OFFICE BASED LABS MARKET SIZE, BY HEALTHCARE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 306. G7 OFFICE BASED LABS MARKET SIZE, BY PREVENTIVE SCREENING, 2017-2032 (USD MILLION)
TABLE 307. G7 OFFICE BASED LABS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 308. BRICS OFFICE BASED LABS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 309. BRICS OFFICE BASED LABS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 310. BRICS OFFICE BASED LABS MARKET SIZE, BY AUTOMATED ANALYZERS, 2017-2032 (USD MILLION)
TABLE 311. BRICS OFFICE BASED LABS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 312. BRICS OFFICE BASED LABS MARKET SIZE, BY POINT-OF-CARE DEVICES, 2017-2032 (USD MILLION)
TABLE 313. BRICS OFFICE BASED LABS MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 314. BRICS OFFICE BASED LABS MARKET SIZE, BY CLINICAL CHEMISTRY, 2017-2032 (USD MILLION)
TABLE 315. BRICS OFFICE BASED LABS MARKET SIZE, BY COAGULATION & HEMOSTASIS, 2017-2032 (USD MILLION)
TABLE 316. BRICS OFFICE BASED LABS MARKET SIZE, BY HEMATOLOGY, 2017-2032 (USD MILLION)
TABLE 317. BRICS OFFICE BASED LABS MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 318. BRICS OFFICE BASED LABS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 319. BRICS OFFICE BASED LABS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 320. BRICS OFFICE BASED LABS MARKET SIZE, BY POINT-OF-CARE TESTS, 2017-2032 (USD MILLION)
TABLE 321. BRICS OFFICE BASED LABS MARKET SIZE, BY ROUTINE TESTS, 2017-2032 (USD MILLION)
TABLE 322. BRICS OFFICE BASED LABS MARKET SIZE, BY SPECIALIZED TESTS, 2017-2032 (USD MILLION)
TABLE 323. BRICS OFFICE BASED LABS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 324. BRICS OFFICE BASED LABS MARKET SIZE, BY DISEASE MONITORING, 2017-2032 (USD MILLION)
TABLE 325. BRICS OFFICE BASED LABS MARKET SIZE, BY HEALTHCARE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 326. BRICS OFFICE BASED LABS MARKET SIZE, BY PREVENTIVE SCREENING, 2017-2032 (USD MILLION)
TABLE 327. BRICS OFFICE BASED LABS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 328. EUROPEAN UNION OFFICE BASED LABS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 329. EUROPEAN UNION OFFICE BASED LABS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 330. EUROPEAN UNION OFFICE BASED LABS MARKET SIZE, BY AUTOMATED ANALYZERS, 2017-2032 (USD MILLION)
TABLE 331. EUROPEAN UNION OFFICE BASED LABS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 332. EUROPEAN UNION OFFICE BASED LABS MARKET SIZE, BY POINT-OF-CARE DEVICES, 2017-2032 (USD MILLION)
TABLE 333. EUROPEAN UNION OFFICE BASED LABS MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 334. EUROPEAN UNION OFFICE BASED LABS MARKET SIZE, BY CLINICAL CHEMISTRY, 2017-2032 (USD MILLION)
TABLE 335. EUROPEAN UNION OFFICE BASED LABS MARKET SIZE, BY COAGULATION & HEMOSTASIS, 2017-2032 (USD MILLION)
TABLE 336. EUROPEAN UNION OFFICE BASED LABS MARKET SIZE, BY HEMATOLOGY, 2017-2032 (USD MILLION)
TABLE 337. EUROPEAN UNION OFFICE BASED LABS MARKET SIZE, BY IMMUNOASSAY, 2017-2032 (USD MILLION)
TABLE 338. EUROPEAN UNION OFFICE BASED LABS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 339. EUROPEAN UNION OFFICE BASED LABS MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 340. EUROPEAN UNION OFFICE BASED LABS MARKET SIZE, BY POINT-OF-CARE TESTS, 2017-2032 (USD MILLION)
TABLE 341. EUROPEAN UNION OFFICE BASED LABS MARKET SIZE, BY ROUTINE TESTS, 2017-2032 (USD MILLION)
TABLE 342. EUROPEAN UNION OFFICE BASED LABS MARKET SIZE, BY SPECIALIZED TESTS, 2017-2032 (USD MILLION)
TABLE 343. EUROPEAN UNION OFFICE BASED LABS MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 344. EUROPEAN UNION OFFICE BASED LABS MARKET SIZE, BY DISEASE MONITORING, 2017-2032 (USD MILLION)
TABLE 345. EUROPEAN UNION OFFICE BASED LABS MARKET SIZE, BY HEALTHCARE DIAGNOSTICS, 2017-2032 (USD MILLION)
TABLE 346. EUROPEAN UNION OFFICE BASED LABS MARKET SIZE, BY PREVENTIVE SCREENING, 2017-2032 (USD MILLION)
TABLE 347. EUROPEAN UNION OFFICE BASED LABS MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 348. ASEAN OFFICE BASED LABS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 349. ASEAN OFFICE BASED LABS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 350. ASEAN OFFICE BASED LABS MARKET SIZE, BY AUTOMATED ANALYZERS, 2017-2032 (USD MILLION)
TABLE 351. ASEAN OFFICE BASED LABS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2017-2032 (USD MILLION)
TABLE 352. ASEAN OFFICE BASED LABS MARKET SIZE, BY POINT-OF-CARE DEVICES, 2017-2032 (USD MILLION)
TABLE 353. ASEAN OFFICE BASED LABS MARKET SIZE, BY TECHNOLOGY TYPE, 2017-2032 (USD MILLION)
TABLE 354. ASEAN OFFICE BASED LABS MARKET SIZE, BY CLINICAL CHEMISTRY, 2017-2032 (USD MILLION)
TABLE 355. ASEAN OFFICE BASED LABS MARKET SIZE, BY COAGULATION & HEMOSTASIS, 2017-2032 (USD MILLION)
TABLE 356. ASEAN OFFICE BASED LABS MARKET SIZE, BY HEMATOLOGY

Companies Mentioned

  • Abbott Laboratories
  • Abionic SA
  • ARKRAY, Inc.
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • bioMérieux SA
  • Boule Diagnostics
  • Danaher Corporation
  • EKF Diagnostics Holdings plc
  • F. Hoffmann-La Roche Ltd
  • Ortho Clinical Diagnostics Inc.
  • QIAGEN N.V.
  • Siemens Healthineers AG
  • STRATEC SE
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages198
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 36.24 Billion
Forecasted Market Value ( USD ) by 2032 $ 55.63 Billion
Compound Annual Growth Rate7.3%
Regions CoveredGlobal
No. of Companies Mentioned16

Related Topics

Related Reports

Office-Based Labs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Office-Based Labs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 180 Pages
  • Global
From
Office-Based Labs Market Outlook 2026-2034: Market Share and Growth Analysis - Product Image

Office-Based Labs Market Outlook 2026-2034: Market Share and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Office-based Labs Market - Global Strategic Business Report - Product Image

Office-based Labs Market - Global Strategic Business Report

  • Report
  • 279 Pages
  • Global
From
United States Office-Based Labs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

United States Office-Based Labs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 80 Pages
  • United States
From
Physician Office Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Physician Office Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 185 Pages
  • Global
From

About the Office Based Lab Market

The Office Based Lab (OBL) market is a subset of the in-office testing market, which focuses on providing laboratory services within a physician's office. OBLs provide a range of services, including clinical chemistry, hematology, immunology, and molecular diagnostics. These services are typically used to diagnose and monitor a variety of conditions, such as diabetes, heart disease, and infectious diseases. OBLs are typically equipped with the necessary equipment and supplies to perform tests, as well as trained personnel to interpret the results. OBLs offer a number of advantages over traditional laboratory services, including improved patient convenience, faster turnaround times, and cost savings. Additionally, OBLs can provide physicians with more timely and accurate information to help them make better decisions about patient care. Some companies in the OBL market include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Quest Diagnostics. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.